Brief: Bluebird bio, ViroMed to develop chimeric antigen receptor T cell therapies

Helixmith

03/12/2015 13:00

Dec 3 (Reuters) - bluebird bio Inc  BLUE.O : 
 * Bluebird bio and ViroMed enter into license agreement for 
   novel antibodies to develop chimeric antigen receptor T cell therapy 
 * Under terms of the agreement, ViroMed will provide bluebird bio exclusive 
   rights to its novel humanized antibody to the target 
 * Says financial terms of the agreement include a $1 million upfront payment 
 * Bluebird bio will leverage proprietary lentiviral gene therapy platform and 
   car t capabilities to develop car t therapies against target 
 * Financial terms also include milestone payments to ViroMed, which together 
   could total over $48 million per licensed product 
 * Says ViroMed is also eligible to receive tiered royalties on product sales 
 * Says bluebird bio will conduct and fund clinical development as well as 
   regulatory and commercial activities 
 * Source text for Eikon  ID:nBwc3cSRVa  
 * Further company coverage  BLUE.O  
 
 ((Bengaluru Newsroom; +1 646 223 8780))